#USA #Cambridge #AI Strategy #Nona Biosciences #Dr. Hongjiang Miao

Nona Biosciences Welcomes Dr. Hongjiang Miao as Chief AI Officer

In a pivotal move to enhance its AI capabilities, Nona Biosciences, a prominent name in the biotechnology sector, has announced the appointment of Dr. Hongjiang Miao as its Chief AI Officer. This strategic decision is intended to propel the company’s A3 strategy—an innovative approach intertwining antibody engineering, artificial intelligence, and automation. Dr. Miao's expertise is expected to transform Nona into a powerhouse of AI-driven drug discovery.

Dr. Miao's Role and Responsibilities

Based in Shanghai, Dr. Miao will report directly to Dr. Di Hong, the CEO of Nona Biosciences. His primary responsibilities will entail leading the Nona AI team, developing robust AI strategies, and ensuring the integration of advanced AI technologies into core business processes. In addition, he will focus on consolidating data resources and algorithmic models, crafting an AI research and development platform, and continuously enhancing the platform's stability and performance through iterative improvements.

With rich experience in AI and biocomputing, Dr. Miao has a commendable track record of spearheading innovative AI technologies. He previously led a team that created China's first high-precision 3D protein structure prediction algorithm, marking significant advancements in the fields of computational biology and therapeutic innovation.

Academic and Professional Background

Dr. Miao holds both bachelor's and master's degrees in mathematics and statistics from the prestigious University of Oxford. He achieved his doctorate at Imperial College London under the renowned Professor Michael J.E. Sternberg, focusing on algorithms that predict protein structure and functionality. Before stepping into his new role at Nona Biosciences, he served as AI CTO at Great Bay Bio and was the head of the XLab laboratory at Tianrang Intelligence.

Insights from Leadership

Dr. Di Hong, CEO of Nona Biosciences, expressed enthusiasm at Dr. Miao's appointment, stating, "We are thrilled to have Dr. Hongjiang Miao on board as our first Chief AI Officer. His exceptional background uniquely positions him to translate algorithmic advancements into tangible discoveries in biologics." Dr. Di emphasized how crucial Dr. Miao’s leadership will be for merging AI technology with Nona's existing expertise in antibody technologies, fostering a synergistic approach that hastens the development of innovative therapeutics.

Conversely, Dr. Miao remarked on the honor of joining a leading biotech company. He stated, "I aim to leverage Nona’s world-class scientific team and innovative platform to navigate the complexities of life science through algorithms. By integrating AI with our biological platforms, we can establish an intelligent engine for drug discovery that will significantly benefit patients and clients alike."

About Nona Biosciences

Nona Biosciences is dedicated to pioneering cutting-edge technologies within the biotechnology landscape, providing comprehensive solutions from Idea to IND (I to I®). Their extensive service offerings in antibody and related discovery include target validation, antibody discovery, and preclinical research. Utilizing its Harbour Mice® platforms, Nona generates fully human monoclonal antibodies suitable for various applications, such as bispecific antibodies, CAR-T therapies, and more.

By fusing advanced technologies like AI and their proprietary systems, Nona aims to reshape the future of drug development, pioneering novel, next-generation therapies that hold transformative potential for healthcare globally.

For further information, please visit www.nonabio.com.